Dr. Sujuan Ba is a prominent leader in the field of cancer research and a co-founder of several organizations that support innovative and collaborative cancer research projects. She is the President & CEO, Founder of the Asian Fund for Cancer Research. She also serves as the President & CEO of the National Foundation for Cancer Research, the Co-founder & CEO of the AIM-HI Accelerator Fund, and the Co-Founder & Board Member of the Global Coalition for Adaptive Research. She is one of the instrumental leaders in establishing GBM AGILE, the first-ever paradigm-shifting adaptive clinical trial platform for brain cancer and other rare cancers. She is also a scientific advisor and a board member for more than half a dozen oncology start-ups.
She is also a scientific advisor and a board member for more than half a dozen oncology start-ups.
Dr. Ba has led the establishment of NFCR’s annual Szent-Györgyi Prize for Progress in Cancer Research, an international prize recognizing outstanding scientific achievement in the war against cancer, and has served continuously as co-chair of the Prize Selection Committee since 2006. The prize has now grown into one of the premier cancer research awards in the world.
Dr. Ba launched the AIM-HI Women’s Venture Competition in 2020, a first-of-its-kind program that provides investment, coaching, and networking opportunities to women-led oncology start-ups. More than 200 women-led oncology start-ups have gone through the rigorous review and judging process of the Women’s Venture Competition platform.
Dr. Ba also established the AIM-HI Beacon Award for Women Leaders in Oncology in 2022, a one-of-its-kind program recognizing outstanding women pioneers who have significantly impacted cancer patients worldwide through developing, commercializing novel technologies, and implementing public policy.
Dr. Ba received the Leadership Award for Global Advocate for Cancer Research from HKBIO in 2023. Dr. Ba also received the NBC4 WORKING 4 THE COMMUNITY Award in 2019, recognizing her outstanding achievements as a scientist, leader, and role model in the STEM field. Dr. Ba also received the inaugural Outstanding Achievement Award from the Society for Neuro-Oncology of the Chinese Medical Doctor Association for her outstanding contribution to international cooperation in 2017. She was named one of the “Top 300 Women Leaders in Global Health” in 2015 by the Graduate Institute of International and Development Studies’ Global Health Programme. She was also awarded the Public Service Award in 2014 by the Chinese Biopharmaceutical Association–USA for her long-term devotion and distinguished service to the global biopharmaceutical community. She was selected to receive the CRS WOMEN IN SCIENCES Award in 2011.
Dr. Ba received her B.S. in radiochemistry from Peking University and her Ph.D. in chemistry from the University of Pennsylvania.
